Found: 16
Select item for more details and to access through your institution.
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1606, doi. 10.1177/13524585221105465
- By:
- Publication type:
- Article
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 7, p. 1121, doi. 10.1177/13524585211028833
- By:
- Publication type:
- Article
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 2, p. 323, doi. 10.1177/13524585211052168
- By:
- Publication type:
- Article
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 11, p. 1727, doi. 10.1177/1352458520977160
- By:
- Publication type:
- Article
4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 11, p. 1309, doi. 10.1177/1352458520923951
- By:
- Publication type:
- Article
Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 14, p. 1896, doi. 10.1177/1352458518810260
- By:
- Publication type:
- Article
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2013, v. 19, n. 5, p. 593, doi. 10.1177/1352458512460604
- By:
- Publication type:
- Article
Glutamate gene polymorphisms predict brain volumes in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2013, v. 19, n. 3, p. 281, doi. 10.1177/1352458512454345
- By:
- Publication type:
- Article
Cognitive progression independent of relapse in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 11/12, p. 1468, doi. 10.1177/13524585241256540
- By:
- Publication type:
- Article
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 10, p. 1296, doi. 10.1177/13524585241272938
- By:
- Publication type:
- Article
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 3, p. 443, doi. 10.1177/13524585231207761
- By:
- Publication type:
- Article
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 2, p. 266, doi. 10.1177/13524585231225855
- By:
- Publication type:
- Article
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 1, p. 44, doi. 10.1177/13524585231212879
- By:
- Publication type:
- Article
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1776, doi. 10.1177/13524585231202320
- By:
- Publication type:
- Article
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 10, p. 1229, doi. 10.1177/13524585231188625
- By:
- Publication type:
- Article
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 8, p. 1001, doi. 10.1177/13524585231159817
- By:
- Publication type:
- Article